Joost L Boormans

11PUBLICATIONS
67CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer diagnosisCancer cell biologyLiquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Feb 27, 2026
Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial.

Jan-Jaap J Mellema, Chantal F Stockem, Cameron Herberts

|Sep 16, 2024
Are primary tumors suitable for biomarker-guided treatment of metastatic urothelial cancer?

Mathijs P Scholtes, Geert J L H van Leenders, Debbie G J Robbrecht

|Aug 02, 2024
Molecular biomarkers of progression in non-muscle-invasive bladder cancer - beyond conventional risk stratification.

Mitchell Olislagers, Florus C de Jong, Vera C Rutten

|Apr 09, 2024
Disease progression in Bacillus Calmètte Guerin unresponsive non-muscle invasive bladder cancer patients with carcinoma in situ, participating in clinical trials on bladder-sparing treatment.

Olga M Pijpers, Joost L Boormans

|Feb 14, 2024
Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer.

Maud Rijnders, J Alberto Nakauma-González, Debbie G J Robbrecht

|May 24, 2023
Non-muscle-invasive bladder cancer molecular subtypes predict differential response to intravesical Bacillus Calmette-Guérin.

Florus C de Jong, Teemu D Laajala, Robert F Hoedemaeker

Pageof 2

Frequent Collaborators

4 joint publications

Geert J L H van Leenders

3 joint publications

Debbie G J Robbrecht

3 joint publications

Tahlita C M Zuiverloon

2 joint publications

Thomas van Doeveren